

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies (as amended)		

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the information listed on the Form PTO-1449 that accompanies this paper. Copies of the cited non-patent documents accompany this submission. Applicant does not represent that a search has been conducted or that the cited documents are prior art against the claims in this application.

Applicant notes that document D316 was cited in a supplemental examination report from the European Patent Office in a counterpart of this application.

This disclosure statement is filed under the provisions of 37 C.F.R. § 1.97(c) prior to a final Office action. Applicant requests that the Director charge the required fee of **\$ 180** (§ 1.17(p)) to our **Deposit Account No. 18-1260**. Any additional fee needed to render this paper timely or proper may be charged to the same account.

The Office has not yet indicated consideration of the disclosure statements filed on 26 September 2000, 1 May 2003 (resubmitted on 11 October 2006), 18 May 2004, and 20 October 2006. Applicant requests that the examiner return initialed form PTO-1449s reflecting

consideration of the cited references. The examiner is invited to contact the undersigned should she desire courtesy copies of any of the documents.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 9 November 1999	Art Unit: 1643

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	D316	5,399,061	1 Dec 1998	Anderson			
	D317	2003/0147885	7 Aug 2003	Anderson			

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	D318	Byrd J.C. et al. <i>Blood</i> 92(10 Suppl. 1): 106a, abst. no. 433, Nov. 1998. Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: preliminary evidence of activity.
	D319	Catovsky D. et al. <i>Eur J. Cancer</i> 31A(13/14): 2146-54 (1995). Key issues in the treatment of chronic lymphocytic leukaemia (CLL).
	D320	Coiffier B. <i>Ann. Oncol.</i> 83(Suppl 1): S73-S74, 2004. New treatment strategies in lymphomas: aggressive lymphomas.
	D321	Ford et al. <i>Highlights in Oncology Practice</i> 16(2): 40-50, 1998. Immunotherapeutic approaches to treatment of B-cell neoplasms: focus on unconjugated antibodies.
	D322	Kaminski M. et al. <i>Proc. Third Conf. on Radioimmunodetection and Radioimmunotherapy of Cancer</i> , Princeton NJ, 15-17 Nov. 1990 (published at <i>Antibody Immunoconj. Radiopharm.</i> 4: 387, 1991), abst. no. 144. 131-I anti-B1: Initial clinical evaluation in B-cell lymphoma.
	D323	Robertson M.J. et al. <i>Blood</i> 79(9): 2229-36, 1992. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.

EXAMINER / Alana M. Harris /	DATE April 11, 2008 CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 1 OF 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/